BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tapper EB, Afdhal NH, Curry MP. Before or After Transplantation? A Review of the Cost Effectiveness of Treating Waitlisted Patients With Hepatitis C. Transplantation. 2017;101:933-937. [PMID: 28437385 DOI: 10.1097/tp.0000000000001611] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Linas BP, Nolen S. A Guide to the Economics of Hepatitis C Virus Cure in 2017. Infect Dis Clin North Am 2018;32:447-59. [PMID: 29778265 DOI: 10.1016/j.idc.2018.02.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
2 Daniel KE, Said A. Considerations When Treating Hepatitis C in a Cirrhotic Transplant Candidate. Curr Gastroenterol Rep. 2018;20:20. [PMID: 29623506 DOI: 10.1007/s11894-018-0626-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
3 Keller J, Marklin G, Okoye O, Desai R, Sura T, Jain A, Varma C, Nazzal M. Treatment of Hepatitis C Post-Liver Transplantation Could Mitigate Discard Rates of Hepatitis C-Positive Deceased Donor Livers and Expand the Donor Pool. J Transplant 2021;2021:6612453. [PMID: 33564467 DOI: 10.1155/2021/6612453] [Reference Citation Analysis]
4 Cholankeril G, Joseph-Talreja M, Perumpail BJ, Liu A, Yoo ER, Ahmed A, Goel A. Timing of Hepatitis C Virus Treatment in Liver Transplant Candidates in the Era of Direct-acting Antiviral Agents. J Clin Transl Hepatol 2017;5:363-7. [PMID: 29226102 DOI: 10.14218/JCTH.2017.00007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
5 Shaffer AA, Thomas AG, Bowring MG, Van Pilsum Rasmussen SE, Cash A, Kucirka LM, Alqahtani SA, Gurakar A, Sulkowski MS, Cameron AM, Segev DL, Durand CM. Changes in practice and perception of hepatitis C and liver transplantation: Results of a national survey. Transpl Infect Dis 2018;20:e12982. [PMID: 30144258 DOI: 10.1111/tid.12982] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
6 Gadiparthi C, Cholankeril G, Perumpail BJ, Yoo ER, Satapathy SK, Nair S, Ahmed A. Use of direct-acting antiviral agents in hepatitis C virus-infected liver transplant candidates. World J Gastroenterol 2018; 24(3): 315-322 [PMID: 29391754 DOI: 10.3748/wjg.v24.i3.315] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
7 Büttner L, Aigner A, Pick L, Brittinger J, Steib CJ, Böning G, Streitparth F. 25 years of experience with transjugular intrahepatic portosystemic shunt (TIPS): changes in patient selection and procedural aspects. Insights Imaging 2022;13:73. [PMID: 35416547 DOI: 10.1186/s13244-022-01216-5] [Reference Citation Analysis]
8 Bunchorntavakul C, Reddy RK. HCV Therapy in Decompensated Cirrhosis before or after Liver Transplantation: A Paradoxical Quandary. Am J Gastroenterol 2018;113:449-52. [PMID: 29206818 DOI: 10.1038/ajg.2017.435] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]